The Zhitong Finance App learned that Bambusa Therapeutics, a biotech company focused on immunology and inflammation, announced the terms of its initial public offering (IPO) on Monday. The company plans to raise $150 million by issuing 9.4 million shares in the price range of $15 to $17 per share. Based on the median value of the proposed offering price range, Bambusa Therapeutics' fully diluted market value would reach $837 million. The company plans to list on NASDAQ under the ticker symbol “BBTX.” The IPO is expected to be priced in the week of October 26, 2026

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.